Interleukin-2 and SOCS-1 proteins involvement in the pathophysiology of severe ovarian hyperstimulation syndrome-a preliminary proof of concept

Journal of Ovarian Research

Yoram Cohen¹  Roy Mashiach¹  Jigal Haas¹  Daniel Lantsberg¹  Olga Dratviman-Storobinsky¹  Raoul Orvieto¹ 

[1] Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

关键词: Pregnancy;    hCG;    SOCS;    Interleukin-2;    Cytokines;    Inflammation;    OHSS;   

Others  :  1151656
DOI  :  10.1186/s13048-014-0106-2

 received in 2014-10-22, accepted in 2014-10-29,  发布年份 2014

【 摘 要 】

Background

Ovarian hyperstimulation syndrome (OHSS), is characterized by marked ovarian enlargement and acute third space fluid sequestration that almost always develops after hCG administration or in early pregnancy. OHSS is similar to vascular leak syndrome (VLS), which may be attributable to the massive increase in systemic inflammatory cytokines. In the present pilot exploratory case series, we sought to evaluate interleukin (IL)-2 and suppressor of cytokine signaling (SOCS)-1 expressions in the peripheral blood mononuclear cells (PBMCs) of patients suffering from severe ovarian hypertimulation syndrome (OHSS), and to examine whether their expressions differ when compared to PBMCs originated from normal early pregnant women (without OHSS).

Methods

Interleukin-2 and SOCS-1 mRNA expressions were examined in PBMCs of 5 women who were hospitalized due to severe OHSS (OHSS group) and 5 women with early IVF pregnancies and without OHSS (control group).

Results

Interleukin-2 mRNA levels in PBMCs were significantly higher in the OHSS as compared to the control groups. Moreover, while SOCS-1 mRNA levels were non-significantly lower, the ratio between IL-2 and SOCS-1 mRNA levels was significantly higher in the OHSS, as compared to the control group.

Conclusions

The inflammatory response to hCG, leading to dysregulation of Il-2 expression and SOCS activation, might be the culprit of OHSS. Additional large prospective studies are required to elucidate the effect of hCG on patients’ inherited inflammatory cascades, which may help discriminating those at risk to develop severe OHSS from those who are not.

【 授权许可】

   
2014 Orvieto et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Navot D, Bergh PA, Laufer N: Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992, 58:249-261.
• [2]Delvigne A, Rozenberg S: Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 2003, 9:77-96.
• [3]Orvieto R, Ben-Rafael Z: Ovarian hyperstimulation syndrome: a new insight into an old enigma. J Soc Gynecol Invest 1998, 5:110-113.
• [4]Orvieto R, Voliovitch I, Fishman P, Ben-Rafael Z: Interleukin-2 and ovarian hyperstimulation syndrome – a pilot study. Hum Reprod 1995, 10:24-27.
• [5]Krebs DL, Hilton DJ: SOCS proteins: negative regulators of cytokine signaling. Stem Cells 2001, 19(5):378-387.
• [6]Fitzgerald JS, Toth B, Jeschke U, Schleussner E, Markert UR: Knocking off the suppressors of cytokine signaling (SOCS): their roles in mammalian pregnancy. J Reprod Immunol 2009, 83:117-123.
• [7]Daegelmann C, Herberth G, Roder S, Herbarth O, Giese T, Kramer U, Behrendt H, Borte M, Heinrich J, Emmrich F, Lehmann I: and for the LISAplus study group. Association between suppressors of cytokine signalling, T-helper type 1/T-helper type 2 balance and allergic sensitization in children. Clin Exp Allergy 2008, 38:438-448.
• [8]Kovanen PE, Young L, Al-Shami A, Rovella V, Pise-Masison CA, Radonovich MF, Powell J, Fu J, Brady JN, Munson PJ, Leonard WJ: Global analysis of IL-2 target genes: identification of chromosomal clusters of expressed genes. Int Immunol 2005, 17:1009-1021.
• [9]Ben-Rafael Z, Orvieto R: Cytokines-involvernent in reproduction. Fertil Steril 1992, 58:1093-1099.
• [10]Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E: Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989, 44:430-440.
• [11]Lyons CA, Wheeler CA, Frishman GN, Hackett RJ, Seifer DB, Haning RV Jr: Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod 1994, 9:792-799.
• [12]Cornish AL, Chong MM, Davey GM, Darwiche R, Nicola NA, Hilton DJ, Kay TW, Starr R, Alexander WS: Suppressor of cytokine signaling-1 regulates signaling in response to interleukin-2 and other gamma c-dependent cytokines in peripheral T cells. J Biol Chem 2003, 278:22755-22761.
• [13]Alexander WS: Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002, 2:410-416.
• [14]Orvieto R: Controlled ovarian hyperstimulation—an inflammatory state. J Soc Gynecol Invest 2004, 11:424-426.
• [15]Oppenheim JJ, Ruscetti FW, Faltynek C: Cytokines. In Basic and Clinical Immunology. 7th edition. Edited by Stites DP, Terr AI. Appleton & Lange, East Norwalk, Connecticut; 1991:78-100.
• [16]Mathur RS, Jenkins JM, Bansal AS: The possible role of the immune system in the aetiopathogenesis of ovarian hyperstimulation syndrome. Hum Reprod 1997, 12:2629-2634.
• [17]Orvieto R, Ben-Rafael Z, Abir R, Bar Hava I, Fisch B, Molad Y: Controlled ovarian hyperstimulation- a state of neutrophil activation. Am J Reprod Immunol 1999, 42:288-291.
• [18]Orvieto R, Schwartz A, Bar Hava I, Abir R, Ashkenazi J, La-Marca A, Ben-Rafael Z: Controlled ovarian hyperstimulation A state of endothelial activation. Am J Reprod Immunol 2000, 44:257-260.
• [19]Orvieto R, Ben Rafael Z, Schwartz A, Abir R, Fisch B, La Marca A, Bar-Hava I: Soluble L-selectin levels during controlled ovarian hyperstimulation. Gynecol Endocrinol 2001, 15:29-33.
• [20]Orvieto R, Genazzani AR, Petraglia F, Schwartz A, Shelef M, Ben-Rafael Z: Interleukin-2 production by cultured human granulosa cells. Int J Fertil Menopausal Stud 1997, 42:297-300.
• [21]Komorowski J, Gradowski G, Stepien H: Effects of hCG and β-hCG on IL-2 and sIL-2R secretion from human peripheral blood mononuclear cells: a dose–response study in vitro. Immunol Lett 1997, 59:29-33.
• [22]Orvieto R, Leites T, Abir R, Bar J, Yoeli R, Feldberg D, Fisch B: Interleukin-2 production in whole blood cell cultures of women undergoing controlled ovarian hyperstimulation for assisted reproduction technology cycles. Am J Reprod Immunol 2003, 50:220-223.
• [23]Rao CV: An overview of the past, present, and future of nongonadal LH/hCG actions in reproductive biology and medicine [editorial]. Semin Reprod Med 2001, 19:7-17.
• [24]Kaaja RJ, Greer IA: Manifestations of chronic disease during pregnancy. JAMA 2005, 294:2751-2757.
• [25]Khil LY, Jun HS, Kwon H, Yoo JK, Kim S, Notkins AL, Yoon JW: Human chorionic gonadotropin is an immune modulator and can prevent autoimmune diabetes in NOD mice. Diabetologia 2007, 50:2147-2155.